Stock Ratings / Health Care / VBIO / financials

NXL (37) NUWE (45) NDRA (48) IRIX (34) ⌘ Pro Terminal →

Valion Bio Inc. (VBIO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: How profitable is Valion Bio Inc. (VBIO)?

In FY 2025 (10-K), VBIO converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

$0.62 -9.13% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.61

Valion Bio Inc. (VBIO) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $1.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.61 (-1.83%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VBIO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (44/100 Composite)

🔍 WHY VBIO SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$2.14-45.3% Next Q

Q2 (-2Q)

Grade D$1.17-19.7% Next Q

Q3 (-1Q)

Grade D$0.94-34% Next Q

Current

Grade D$0.62-6.5% Hist 90D α

Trajectory: C- (52) → D (44)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a VBIO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While VBIO currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.23) and Max Pain ($0.65) forces dealer call-delta covering toward $70.88.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VBIO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “VBIO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 44%NO 56%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How VBIO Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $1.2M

FY24

Rev $780.0K

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-0.2%	-$8.9M	-$7.0M	-45%
FY 2024	$780.0K	0.3%	-80%	-$5.7M	-$5.7M	-45%
FY 2023	$1.2M	52%	-80%	-$8.2M	-$8.5M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VBIO)

✓Walkthrough of VBIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VBIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -97.47%📐 HORIZONTAL RANGE

2026-10-30O $0.60H $0.62L $0.52C $0.62VOL 217.6K

RES: $34.69SUP: $-7.88SMA50: $2.23SMA200: $15.10

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VBIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VBIO Butterfly Map → + Track VBIO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VBIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VBIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VBIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VBIO)

Health Care Rank #534 of 1016 ⚔️ NXL vs VBIO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VBIO vs. NXL, NUWE, NDRA, IRIX)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Valion Bio Inc. (VBIO) ranks #534 by composite RQD confidence (44/100, grade D) and #1013 by equity capitalization ($1.3M). Within this direct 5-issuer industry benchmark cohort, VBIO leads on earnings valuation at N/A trailing P/E, while VBIO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. NDRA currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with VBIO at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VBIO ACTIVE Valion Bio Inc.	D	44/100	—	—	-35.0%	-9.13%	$1.3M	Benchmark Subject
NXL Nexalin Technology Inc.	D-	37/100	—	79.7%	-35.0%	0.00%	$1.9M	/nxl-vs-vbio →
NUWE Nuwellis Inc.	D	45/100	—	62.0%	-35.0%	+2.12%	$2.3M	/nuwe-vs-vbio →
NDRA ENDRA Life Sciences Inc.	D	48/100	—	—	-35.0%	+2.95%	$7.3M	/ndra-vs-vbio →
IRIX IRIDEX Corporation	E	34/100	—	36.5%	-35.0%	-2.92%	$12.7M	/irix-vs-vbio →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001787740

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Valion Bio Inc. (VBIO) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $780.0K , and -100.0% cumulative change since FY2023) , GAAP net income of -$8.9M, operating cash flow of -$7.0M, and free cash flow of -$7.0M (-22.9% YoY). On the balance sheet, VBIO closed FY2025 with $31.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$8.9M	-$7.0M	-$7.0M	$31.6M	—
FY2024 (FY)	2024-12-31	$780.0K	-$5.7M	-$5.7M	-$5.7M	$2.8M	—
FY2023 (FY)	2023-12-31	$1.2M	-$8.2M	-$8.5M	-$8.5M	—	—

3. VBIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Valion Bio Inc. (NASDAQ: VBIO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $0.62 (-9.13% 1D, market cap $1.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, VBIO ranks #534 in composite RQD confidence.

How does VBIO compare to NXL and NUWE in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), VBIO carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NXL (Nexalin Technology Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.9M) and NUWE (Nuwellis Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.3M). Among the 5-stock peer group, VBIO leads on earnings multiple (N/A) while VBIO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VBIO?

Per VBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001787740), Valion Bio Inc. generated $0 in revenue (-100.0% YoY), -$8.9M in net income, and -$7.0M in free cash flow against $31.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VBIO trading relative to its 50-day, 200-day, and 52-week technical levels?

VBIO last traded at $0.62 (-9.13% on volume of 140,013 shares), positioning the stock -72.20% below its 50-day simple moving average ($2.23) and -95.89% below its 200-day simple moving average ($15.10). Across its 52-week range of $0.52 to $67.50, VBIO sits at the 0.1% percentile with a 14-day RSI of 20.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.70).

VBIO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Valion Bio Inc. (VBIO)?

In FY 2025 (10-K), VBIO converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: VBIO RQD Cockpit VBIO 12M Forecast VBIO Earnings & Move VBIO Dividends & DRIP VBIO Insiders & 13F VBIO Whale Options VBIO Profit Sankey VBIO News & Why